© 2024 SEISMIC TX. ALL RIGHTS RESERVED.
Cambridge, Mass., December 9, 2022 – Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, announced today the company was selected as the Emerging Company of the Year in Life Sciences by the New England Venture Capital Association (NEVCA) in its 10th annual NEVY Awards, which recognizes and celebrates the top innovators, investors and companies in the region.
“We are thrilled to be named Emerging Company of the Year in Life Sciences and thank the New England Venture Capital Association for recognizing our vision and momentum,” said Jo Viney, PhD, CEO of Seismic Therapeutic. “We look ahead with excitement as our dynamic team works to advance our IMPACT platform to develop innovative immunology therapies that make a difference for patients.”
Seismic Therapeutic representatives received the award on December 8th at the annual celebratory event at the House of Blues in Boston. The NEVYs honor both early- and late-stage companies, as well as the venture capitalists who support them, and cover a broad spectrum of the region’s thriving industry clusters, including technology, life sciences, healthcare and medtech.
About the New England Venture Capital Association
The New England Venture Capital Association (NEVCA) works toward a collaborative, inclusive, and prosperous innovation ecosystem. Through unique programs, critical policy work, and dynamic local events and regional marketing, the NEVCA invests in the entrepreneurial ecosystem on behalf of the VC community. VCs are only as successful as the entrepreneurs in whom they invest and the environments in which those investments grow. We don’t just host events: we act as a network, catalyst, and resource for the innovation economy, from celebrations to education; legislative advocacy to workforce development. Follow @NewEnglandVC on Twitter, or check out www.newenglandvc.org.
About Seismic Therapeutic
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to treat adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
This links to an external website.